MedTrace Logo

Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)

NCT01703052 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2020-07-31

No results posted yet for this study

Summary

This study is designed to investigate the safety, tolerability and pharmacokinetics of inhaled CHF 6001 after single and multiple doses in healthy volunteers.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

CHF 6001 SD or placebo

Dry Powder Inhaler

DRUG

CHF 6001 MD or placebo

Dry Powder Inhaler

Sponsors & Collaborators

  • Chiesi Farmaceutici S.p.A.

    lead INDUSTRY

Principal Investigators

  • Stuart Mair, MD · Quotient Clinical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01703052 on ClinicalTrials.gov